News

American Association of Individual Investors2d
Why Allogene Therapeutics, Inc.’s (ALLO) Stock Is Up 6.64%
Allogene Therapeutics, Inc.’s ALLO share price has surged by 6.64%, which has investors questioning if this is right time to ...
Zacks Investment Research on MSN8d
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug
Allogene Therapeutics ALLO announced that the FDA has granted three fast track designations to its investigational ...
Equities Analysts Issue Forecasts for ALLO Q1 Earnings
Equities research analysts at Zacks Research issued their Q1 2027 earnings per share estimates for Allogene Therapeutics in a ...
Business Insider1mon
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
March 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™) products for ...
Investing1mon
Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company specializing in allogeneic CAR-T cell therapies, stands at a critical juncture in its development. According to ...
Business Insider1mon
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for ...